Home 10 of the latest digital health funding deals

10 of the latest digital health funding deals

Date Company Amount Round Category
Dec 23, 2022 Parallel Bio $4.3M Seed Biotech
Lead investor(s): Refactor Capital
Also participating: Breakout Ventures; Jeff Dean, SVP of Google AI; Y Combinator; several biotech-focused funds; and senior executives at global pharmaceutical companies
Parallel Bio unlocks the human body's own power to cure disease. It developed the first platform that replicates the human immune system in a dish for drug discovery and development. It models human disease more realistically and accurately than animal testing — leading to the fastest path to treatments and cures that work for more people. Through its combination of immune organoids, machine learning and robotics, the platform represents the complexity of disease and the diversity of patients at population scale. read more
Date Company Amount Round Category
Dec 22, 2022 Doctor Anywhere $38.8M Series C Healthcare platform
Lead investor(s): Novo Holdings
Also participating: Asia Partners, Kamet Capital, Square Peg, IHH Healthcare, EDBI, OSK-SBI Venture Partners
The funding will be used to accelerate growth and to partly fund the acquisition of Asian Healthcare Specialists. It comes just over a year after the company raised a US$65.7 million Series C in August 2021 in one of the largest private funding rounds ever raised by a healthtech company in Southeast Asia. This brings the total capital raised by Doctor Anywhere to nearly US$140 million. read more
Date Company Amount Round Category
Dec 21, 2022 Biomica $20M Other Microbiome
Lead investor(s): Shanghai Healthcare Capital
Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene. The financing round will enable Biomica to forge ahead, developing its pipeline of microbiome-based therapeutics. Biomica plans to use the proceeds to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial; scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD); as well as advance additional programs. read more
Date Company Amount Round Category
Dec 20, 2022 Carallel $8.2M Series A Caregiver tools
Lead investor(s): FCA Venture Partners
Also participating: 450 Ventures, Create Health Ventures, Gratitude Railroad, Loud Capital, Wanxiang Healthcare Investments
Carallel is a leading provider of human-centered guidance and digital tools for family caregivers. It already supports more than 400,000 Medicare Advantage and commercially insured members and their caregivers nationally. The company plans to use the new funding to expand its reach in both the Medicare Advantage and commercial markets. The funds will also support increased development of dynamic digital experiences, expansion of peer-to-peer support, and targeted care interventions. read more
Date Company Amount Round Category
Dec 20, 2022 Nectar $16.5M Series A Allergy care
Lead investor(s): Harmony Partners
Also participating: Juxtapose, Obvious Ventures
Led by CEO Kenneth Chahine, Nectar is building a vertically-integrated platform for allergies, including a hybrid virtual and physical clinic model, compounding pharmacy, lab testing facility, and an allergist physician network to align incentives and deliver customer experiences. The company offers custom-formulated drops for under the tongue, delivered right to patients' homes. It intends to use the funds to invest in three key areas in 2023, scaling its virtual care platform nationwide, launching its first physical location to comprehensively treat allergies, and initiating clinical studies. read more
Date Company Amount Round Category
Dec 16, 2022 In-Med Prognostics $2.13M Other Imaging
Lead investor(s): Exxora
Also participating: prominent angels
In-Med Prognostics offers AI powered image processing proprietary software for neurologist decision support and radiologist workflow enhancement. The company is the first in the world to provide ethnicity specific neuro assessment reports and multi-modal data processing capability to develop integrated digital biomarkers, claimed by the firm in a statement. read more
Date Company Amount Round Category
Dec 16, 2022 Aktivolabs $10M Series A Chronic care
Lead investor(s): Adaptive Capital Partners, Seeds Capital, Mitsui
Also participating: HH Investments, Govin Capital
Founded in 2017, Aktivolabs uses real-time data from smartphones and wearable devices to predict and prevent chronic diseases. It also helps insurance firms create new products that relate to their policyholders' lifestyles. It currently operates in Singapore, Hong Kong, India, Japan, Australia, the Philippines, Taiwan, Malaysia, Indonesia, Vietnam, Thailand, Macau, and the United Arab Emirates. read more
Date Company Amount Round Category
Dec 16, 2022 Override $3.5M Seed Pain management
Lead investor(s): 7wireVentures, Martin Ventures
Also participating: SignalFire, Confluent Health
Override is a non-opioid solution that bridges the gaps in traditionally fragmented, one-size-fits-none chronic pain treatment. Even though chronic pain is known to affect more than just the body, pain care typically operates in silos — surgeons performing surgeries, primary care doctors prescribing opioids, psychologists conducting psychotherapy — without any communication between providers. Override is a virtual, one-stop-shop that matches patients with a team of chronic pain specialists in pain medicine, physical therapy, and behavioral health. These specialists treat Override patients individually and work together as a team. read more
Date Company Amount Round Category
Dec 15, 2022 MyHealth Africa $1M Seed Healthcare platform
Lead investor(s): GIIG Africa Fund
Also participating: Japanese-based Samurai VC, a family office, existing investors
Kenya-based MyHealth Africa, an integrated healthcare platform changing how people access medical services, by connecting patients with local and international health specialists and hospitals, is growing its reach in Africa, and plans to further expand in Middle East and South Asia next year. read more
Date Company Amount Round Category
Dec 15, 2022 Synchron $75M Series C Brain-computer interface
Lead investor(s): ARCH Venture Partners
Also participating: Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, Project X, Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group, University of Melbourne
Synchron, which is the endovascular brain-computer interface (BCI) company, will use the funds to accelerate development of its first platform product (Synchron Switch BCI), and launch a pivotal clinical trial. Ari Nowacek from ARCH Venture Partners will join Synchron's Board of Directors, and ARCH Co-Founder and Managing Director Robert Nelsen will join as Board Observer. read more

Get the most important digital health news delivered straight to your inbox, every Monday. Subscribe to our FREE newsletter!